Antimitotic activity of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones

Journal of Medicinal Chemistry

Volumn 47, Issue 20, 2004, Pages 4964-4970

  Hadjeri, Mohamed ^a   Peiller, Eva Laure ^b   Beney, Chantal ^a   Deka, Nabajyoti ^a   Lawson, Martin A ^a   Dumontet, Charles ^b   Boumendjel, Ahcène ^a  

^a Laboratoire de Pharmacochimie   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 FLUOROPHENYL) 5 HYDROXY 7 METHOXY 4 QUINOLONE; 5 HYDROXY 7 METHOXY 2 PHENYL 4 QUINOLONE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; FUNCTIONAL GROUP; HYDROXYL GROUP; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MITOSIS INHIBITION; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE; HUMANS; K562 CELLS; MITOSIS; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLIUM SALTS; THIAZOLES;

EID: 4544355911     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049876x     Document Type: Article

References (23)

1. Tung, D. T.; Jamison, T. F.; Schreiber, S. L. Understanding and controlling the cell cycle with natural products. Chem. Biol. 1996, 3, 623-639.
2. Rowinsky, E. K.; Donehower, R. C. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. 1991, 52, 35-84.
3. Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle. Med. Res. Rev. 1998, 18, 259-296.
4. Hamel, E. Interactions of tubulin with small ligands. In Microtubule Proteins; Avila, J., Ed.; CRC Press: Boca Raton, FL, 1990; pp 89-191.
5. Kuo, S.-C.; Lee, H. Z.; Juang, J. P.; Lin, Y. T.; Wu, T. S.; Cheng, J. J.; Lednicer, D.; Paull, K. D.; Lin, C. M.; Hamel, E.; Lee, K.-H. Synthesis and cytotoxicity of 1,6,7,8- and 4′-substituted 2-phenyl-4-quinolones and related compounds: Identification as antimitotic agents interacting with tubulin. J. Med. Chem. 1993, 36, 1146-1156.
6. Li, L.; Wuang, H. K.; Kuo, S.-C.; Lednicer, D.; Lin, C. M.; Hamel, E.; Lee, K.-H. 2′,3′,4′,5′,5,6,7-substituted 2-phenyl-4-quinolones and related compounds: their synthesis and inhibition of tubulin polymerization. J. Med. Chem. 1994, 37, 1126-1135.
7. Li, L.; Wang, H. K.; Kuo, S.-C.; Wu, T. S.; Mauger, A.; Lin, C. M.; Hamel, E.; Lee, K.-H. Synthesis and biological evaluation of 3′,6,7-substituted 2-phenyl-4-quinolones as antimitotic antitumor agents. J. Med. Chem. 1994, 37, 3400-3407.
8. Xia, Y.; Yang, Z.-Y.; Morris-Natschke, S. L.; Lee, K.-H. Recent advances in the discovery and development of quinolones and analogues as antitumor agents. Curr. Med. Chem. 1999, 6, 179-194.
9. Xia, Y.; Yang, Z.-Y.; Xia, P.; Hackel, T.; Hamel, E.; Mauger, A.; Wu, J.-H.; Lee, K.-H. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic and antitumor agents. J. Med. Chem. 2001, 44, 3932-3936.
10. Weigt, M.; Wiese, M. A comparative molecular field analysis of inhibitors of tubulin polymerization. Quant. Struct.-Act. Relat. 2000, 19, 142-148.
11. Boumendjel, A.; Di Pietro, A.; Dumontet, C.; Barron, D. Recent advances in the discovery of flavonoids and analogues with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med. Res. Rev. 2002, 22, 512-529.
12. Beutler, J. A.; Hamel, E.; Vlietinck, A. J.; Haemers, A.; Rajan, P.; Roitman, J. N.; Cardellina, J. H.; Boyd, M. R. Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J. Med. Chem. 1998, 41, 2333-2338.
13. Shi, Q.; Chen, K.; Li, L.; Chang, J. J.; Autry, C.; Kozuka, M.; Konoshima, T.; Estes, J. R.; Lin, C. M.; Hamel, E.; McPhail, A. T.; McPhail, D. R.; Lee, K. H. Antitumor agents, 154. Cytotoxic and antimitotic flavonols from Polanisia dodecandra. J. Nat. Prod. 1995, 58, 475-482.
14. Cody, V.; Middleton, E.; Harborne, J. B. Progress in Clinical Biological Research. Plant Flavonoids in Biology and Medicine; Alan R Liss: New York, 1988.
15. De Azevedo, F. W.; Mueller-Dieckmann, H. J.; Schulze-Gahmen, U.; Worland, P. J.; Saussville, E.; Kim, S. H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2735-2740.
16. Sicheri, F.; Moarefi, I.; Kuriyan, J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997, 385, 602-609.
17. Hadjeri, M.; Mariotte, A.-M.; Boumendjel, A. Alkylation of 2-phenyl-4-quinolones: Synthetic and structural studies. Chem. Pharm. Bull. 2001, 10, 1352-1355.
18. Kelly, M.; Hartwell, J. The biological effects and the chemical composition of podophyllin. A Review. J. Natl. Cancer Inst. 1954, 14, 967-1010.
19. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Isolation and structures of the strong cell growth and tubulin inhibitor combrestatin A-4. Experientia 1989, 45, 209-211.
20. Boyd, M. R. In Cancer: Principles and Practice of Oncology Updates; De Vita, V. T., Hellman, S., Rosenberg, S. A., Eds.; J. B. Lippincoft: Philadelphia, 1989; pp 1-12.
21. Boyd, M. R. Status of the NCI preclinical antitumor drug discovery screen. In Cancer: Principles and Practice of Oncology Updates; De Vita, V. T., Hellman, S., Rosenberg, S. A., Eds.; J. B. Lippincoft: Philadelphia, 1989; pp 1-12.
22. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Woiff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen utilizing a derived panel of human tumor cell lines: Development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092.
23. Galmarini, C. M.; Falette, N.; Tabone, E.; Levrat, C.; Britten, R.; Voorzanger-Rousselot, N.; Roesch-Gateau, O.; Vanier-Viornery, A.; Puisieux, A.; Dumontet, C. Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity. Br. J. Cancer 2001, 85, 902-908.